Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Dr Jess Morgan at Leeds Children’s Hospital and Dr Gemma Bryan at University of Surrey hope to understand more about how hospitals are offering chemotherapy that needs to be given as infusions over a number of days.
Discovering what causes nerve cells to stop working and die years after a Langerhans cell histiocytosis diagnosis.
Looking for repurposed treatments that can fight leukaemia cells in very young children.
Creating a new immunotherapy that will attacks collagen in cancer cells, and testing whether it is effective in model systems to make it the best it can be.
Investigating cancer stem cells in Wilms tumour to see whether they are responsible for relapse, and to understand how that happens.
Looking at what extra pieces of chromosomes do in neuroblastoma and how these work with the MYCN protein to convert healthy cells into cancer cells.
Understanding how the MYCN protein changes the amounts of other proteins in the cell by changing the way DNA is processed and translated.
Modifying current immunotherapy so that it doesn't cause damage to nerve cells and instead targets three molecules to help kill neuroblastoma cells more effectively.